Accès ouvert déclaré 2022 article

Characteristics and outcomes of COVID-19 patients with and without asthma from the United States, South Korea, and Europe

Daniel R. Morales, Anna Ostropolets, Lana Yin Hui Lai, Anthony G. Sena, Scott L. DuVall, Marc A. Suchard, Katia M.C. Verhamme, Peter Rjinbeek, Joe Posada, Waheed‐Ul‐Rahman Ahmed, Thamer Alshammary, Heba Alghoul, Osaid H. Alser, Carlos Morgado Areia, Clair Blacketer, Edward Burn, Paula Casajust, Seng Chan You, Dalia Dawoud, Asieh Golozar, Menchung Gong, Jitendra Jonnagaddala, Kristine E. Lynch, Michael Edwin Matheny, Evan P. Minty, Fredrik Nyberg, Albert Prats‐Uribe, Martina Recalde, Christian Reich, Martijn Scheumie, Karishma Shah, Nigam Haresh Shah, Lisa M. Schilling, David Vizcaya, Lin Zhang, George M. Hripcsak, Patrick B. Ryan, Daniel Prieto‐Alhambra, Talita Durate-Salles, Kristin Kostka

8Citations signalées, ce qui n’est pas une note de qualité

24Institutions déclarées

11Pays d’affiliation déclarés

Rattachement africain : gb, dk, us, nl, sa, ps, kr, ca, se, es, cn. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Objective: Large international comparisons describing the clinical characteristics of patients with COVID-19 are limited. The aim of the study was to perform a large-scale descriptive characterization of COVID-19 patients with asthma.Methods: We included nine databases contributing data from January to June 2020 from the US, South Korea (KR), Spain, UK and the Netherlands. We defined two cohorts of COVID-19 patients (‘diagnosed’ and ‘hospitalized’) based on COVID-19 disease codes. We followed patients from COVID-19 index date to 30 days or death. We performed descriptive analysis and reported the frequency of characteristics and outcomes in people with asthma defined by codes and prescriptions.Results: The diagnosed and hospitalized cohorts contained 666,933 and 159,552 COVID-19 patients respectively. Exacerbation in people with asthma was recorded in 1.6–8.6% of patients at presentation. Asthma prevalence ranged from 6.2% (95% CI 5.7–6.8) to 18.5% (95% CI 18.2–18.8) in the diagnosed cohort and 5.2% (95% CI 4.0–6.8) to 20.5% (95% CI 18.6–22.6) in the hospitalized cohort. Asthma patients with COVID-19 had high prevalence of comorbidity including hypertension, heart disease, diabetes and obesity. Mortality ranged from 2.1% (95% CI 1.8–2.4) to 16.9% (95% CI 13.8–20.5) and similar or lower compared to COVID-19 patients without asthma. Acute respiratory distress syndrome occurred in 15–30% of hospitalized COVID-19 asthma patients.Conclusion: The prevalence of asthma among COVID-19 patients varies internationally. Asthma patients with COVID-19 have high comorbidity. The prevalence of asthma exacerbation at presentation was low. Whilst mortality was similar among COVID-19 patients with and without asthma, this could be confounded by differences in clinical characteristics. Further research could help identify high-risk asthma patients.KEY MESSAGESAsthma prevalence in COVID-19 patients varied internationally (5.2–20.5%).The prevalence of asthma exacerbation at presentation with COVID-19 in diagnosed and hospitalized patients was low.Comorbidities were common in COVID-19 patients with asthma.Supplemental data for this article is available online at https://doi.org/10.1080/02770903.2021.2025392 .

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref: Characteristics and outcomes of COVID-19 patients with and without asthma from the United States, South Korea, and Europe
Date Crossref: 11/02/2022
Éditeur: Informa UK Limited
Type: journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Où se fait cette recherche

University of Dundee Division of Population Health and Genomics pays non établi dans la notice
Université ou école supérieure
University of Southern Denmark Department of Public Health pays non établi dans la notice
Université ou école supérieure
Genomics (United Kingdom) pays non établi dans la notice
Entreprise
Columbia University Department of Biomedical Informatics pays non établi dans la notice
Université ou école supérieure
University of Manchester pays non établi dans la notice
Université ou école supérieure
Janssen (United States) pays non établi dans la notice
Entreprise
University of Utah pays non établi dans la notice
Université ou école supérieure
University of California pays non établi dans la notice
Université ou école supérieure
Applied Biomathematics (United States) pays non établi dans la notice
Entreprise
Erasmus MC pays non établi dans la notice
Établissement de santé
Erasmus University Rotterdam pays non établi dans la notice
Université ou école supérieure
Stanford University pays non établi dans la notice
Université ou école supérieure

Division of Population Health and Genomics — University of Dundee, Department of Public Health — University of Southern Denmark et Genomics (United Kingdom), avec 9 autres affiliations.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Chronic Obstructive Pulmonary Disease (COPD) ResearchCOVID-19 Clinical Research StudiesCOVID-19 and healthcare impacts

Lire en accès ouvert Consulter la publication primaire Ouvrir le DOI